[go: up one dir, main page]

PA8568401A1 - Inhibidores pirimidina y piridina biciclicos de la p38 quinasa - Google Patents

Inhibidores pirimidina y piridina biciclicos de la p38 quinasa

Info

Publication number
PA8568401A1
PA8568401A1 PA20038568401A PA8568401A PA8568401A1 PA 8568401 A1 PA8568401 A1 PA 8568401A1 PA 20038568401 A PA20038568401 A PA 20038568401A PA 8568401 A PA8568401 A PA 8568401A PA 8568401 A1 PA8568401 A1 PA 8568401A1
Authority
PA
Panama
Prior art keywords
quinasa
pyrimidine
bicycle
pyridine inhibitors
pyridine
Prior art date
Application number
PA20038568401A
Other languages
English (en)
Inventor
Jian Jeffrey Chen
Nolan James Dewdney
Christoph Martin Stahl
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PA8568401A1 publication Critical patent/PA8568401A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA PRESENTE INVENCION REVELA COMPUESTOS CORRESPONDIENTES A LA FORMULA, EN DONDE A,R,X,Y,R,R1, Y R2 SON TAL COMO SE DEFINEN, FORMULACIONES FARMACEUTICAS, METODOS DE FABRICACION Y USOS DE LOS MISMOS EN EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR LA QUINASA P38.
PA20038568401A 2002-03-07 2003-03-06 Inhibidores pirimidina y piridina biciclicos de la p38 quinasa PA8568401A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36237302P 2002-03-07 2002-03-07
US43050802P 2002-12-03 2002-12-03

Publications (1)

Publication Number Publication Date
PA8568401A1 true PA8568401A1 (es) 2003-12-10

Family

ID=27791709

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20038568401A PA8568401A1 (es) 2002-03-07 2003-03-06 Inhibidores pirimidina y piridina biciclicos de la p38 quinasa

Country Status (19)

Country Link
US (3) US7091347B2 (es)
EP (1) EP1485390B1 (es)
JP (1) JP4187657B2 (es)
KR (1) KR100714519B1 (es)
CN (1) CN100386328C (es)
AR (1) AR038864A1 (es)
AT (1) ATE410429T1 (es)
AU (1) AU2003210388B2 (es)
BR (1) BR0308232A (es)
CA (1) CA2477721A1 (es)
DE (1) DE60323946D1 (es)
ES (1) ES2314224T3 (es)
MX (1) MXPA04008592A (es)
PA (1) PA8568401A1 (es)
PE (1) PE20040189A1 (es)
PL (1) PL372886A1 (es)
RU (1) RU2301233C2 (es)
TW (1) TW200306194A (es)
WO (1) WO2003074530A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003246972A1 (en) 2002-08-06 2004-02-23 Astrazeneca Ab Condensed pyridines and pyrimidines with tie2 (tek) activity
US7319102B1 (en) * 2003-12-09 2008-01-15 The Procter & Gamble Company Pyrrolo[2,3-d]pyrimidine cytokine inhibitors
DE602004025504D1 (de) * 2003-12-23 2010-03-25 Novartis Ag Bicyclische heterocyclische p-38-kinase-inhibitoren
EP1713806B1 (en) 2004-02-14 2013-05-08 Irm Llc Compounds and compositions as protein kinase inhibitors
CA2557268A1 (en) 2004-02-27 2005-09-15 F. Hoffmann-La Roche Ag Indazole derivatives and pharmaceutical compositions containing them
BRPI0508220A (pt) * 2004-02-27 2007-07-17 Hoffmann La Roche derivados de pirazol heteroarila fundidos
KR100843526B1 (ko) * 2004-02-27 2008-07-03 에프. 호프만-라 로슈 아게 피라졸의 접합 유도체
WO2005107760A1 (en) * 2004-04-30 2005-11-17 Irm Llc Compounds and compositions as inducers of keratinocyte differentiation
KR20070085286A (ko) * 2004-10-29 2007-08-27 티보텍 파마슈티칼즈 리미티드 Ｈｉｖ를 저해하는 바이사이클릭 피리미딘 유도체
GB0427604D0 (en) * 2004-12-16 2005-01-19 Novartis Ag Organic compounds
AU2006283941A1 (en) * 2005-08-25 2007-03-01 F. Hoffmann-La Roche Ag P38 MAP kinase inhibitors and methods for using the same
CA2649543A1 (en) * 2006-04-21 2007-11-01 Amgen Inc. Thieno-[2,3-d]pyrimidine and thieno-pyridazine compounds and methods of use
TWI398252B (zh) * 2006-05-26 2013-06-11 Novartis Ag 吡咯并嘧啶化合物及其用途
RU2540074C2 (ru) * 2007-06-21 2015-01-27 Кара Терапеутикс, Инк Производные имидазопиразина или имидазодиазепина, активные в отношении рецептора св2
RU2345996C1 (ru) * 2007-07-17 2009-02-10 Андрей Александрович Иващенко Аннелированные азагетероциклические амиды, включающие пиримидиновый фрагмент, способ их получения и применения
RU2341527C1 (ru) * 2007-07-17 2008-12-20 Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" Аннелированные азагетероциклы, включающие пиримидиновый фрагмент, способ их получения и ингибиторы pi3k киназ
CA2714177A1 (en) 2008-02-06 2009-08-13 Novartis Ag Pyrrolo [2,3-d] pyridines and use thereof as tyrosine kinase inhibitors
TW201002713A (en) 2008-04-09 2010-01-16 Organon Nv Pyrrolo[2,3-d]pyrimidin-2-yl-amine derivatives as PKC-theta inhibitors
CN102186856B (zh) 2008-08-22 2014-09-24 诺华股份有限公司 作为cdk抑制剂的吡咯并嘧啶化合物
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
US20130102601A1 (en) * 2011-10-21 2013-04-25 F. Hoffmann-La Roche Ltd Pyrimidin-4-one derivatives and their use in the treatment, amelioration or prevention of a viral disease
GB201216018D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Pharmacologically active compounds
GB201216017D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
CN103254194B (zh) * 2013-05-17 2015-07-08 浙江师范大学 一种8-硫杂黄嘌呤化合物的制备方法
GB201403536D0 (en) 2014-02-28 2014-04-16 Cancer Rec Tech Ltd Inhibitor compounds
EP3287463A4 (en) * 2015-04-24 2018-07-11 Guangzhou Maxinovel Pharmaceuticals Co., Ltd. Condensed-ring pyrimidylamino derivative, preparation method therefor, and intermediate, pharmaceutical composition and applications thereof
WO2017151409A1 (en) 2016-02-29 2017-09-08 University Of Florida Research Foundation, Incorporated Chemotherapeutic methods
GB201709840D0 (en) 2017-06-20 2017-08-02 Inst Of Cancer Research: Royal Cancer Hospital Methods and medical uses
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
EP3692144A1 (en) 2017-10-05 2020-08-12 Fulcrum Therapeutics, Inc. Use of p38 inhibitors to reduce expression of dux4
SG11202004966PA (en) * 2017-12-21 2020-06-29 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising a dementia
WO2019123375A1 (en) * 2017-12-21 2019-06-27 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising motor neuron diseases

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4835157A (en) * 1988-03-15 1989-05-30 Ortho Pharmaceutical Corporation Thieno- and furopyrimidine-2,4-dione piperidine derivatives as serotonin antagonists and alpha adrenergic blocking agents
AU2395095A (en) 1994-04-29 1995-11-29 G.D. Searle & Co. Method of using (h+/k+) atpase inhibitors as antiviral agents
US6075037A (en) 1994-06-09 2000-06-13 Smithkline Beecham Corporation Endothelin receptor antagonists
WO1995033752A1 (en) 1994-06-09 1995-12-14 Smithkline Beecham Corporation Endothelin receptor antagonists
DK0831829T3 (da) * 1995-06-07 2003-12-15 Pfizer Heterocykliske, ringkondenserede pyrimidinderivater
EP0960102A1 (en) 1996-07-08 1999-12-01 Du Pont Pharmaceuticals Company AMIDINOINDOLES, AMIDINOAZOLES, AND ANALOGS THEREOF AS INHIBITORS OF FACTOR Xa AND OF THROMBIN
WO1998006715A1 (en) * 1996-08-09 1998-02-19 Smithkline Beecham Corporation Novel piperazine containing compounds
CA2263907A1 (en) 1996-08-30 1998-03-05 Christopher Leighon Jordan Nonclassical pyrrolo[2,3-d]pyrimidine antifolates
PL340412A1 (en) * 1997-10-20 2001-01-29 Hoffmann La Roche Bicyclic kinase inhibitors
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
WO2000038683A1 (en) 1998-12-23 2000-07-06 Du Pont Pharmaceuticals Company THROMBIN OR FACTOR Xa INHIBITORS
CZ27399A3 (cs) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
CA2396276A1 (en) 2000-01-07 2001-07-12 Universitaire Instelling Antwerpen Purine derivatives, process for their preparation and use thereof
DE60119124T2 (de) * 2000-08-14 2006-11-30 Ortho-Mcneil Pharmaceutical, Inc. Substituierte pyrazole
AU2002333524A1 (en) * 2001-09-11 2003-03-24 Glaxosmithkline K.K. Furo-and thienopyrimidine derivatives as angiogenesis inhibitors

Also Published As

Publication number Publication date
US20030207900A1 (en) 2003-11-06
US7439247B2 (en) 2008-10-21
JP4187657B2 (ja) 2008-11-26
EP1485390B1 (en) 2008-10-08
CN1639168A (zh) 2005-07-13
US20060084803A1 (en) 2006-04-20
RU2301233C2 (ru) 2007-06-20
BR0308232A (pt) 2004-12-28
CN100386328C (zh) 2008-05-07
MXPA04008592A (es) 2004-12-06
PL372886A1 (en) 2005-08-08
EP1485390A1 (en) 2004-12-15
US7449472B2 (en) 2008-11-11
CA2477721A1 (en) 2003-09-12
KR100714519B1 (ko) 2007-05-07
RU2004129768A (ru) 2005-08-27
DE60323946D1 (de) 2008-11-20
KR20040091084A (ko) 2004-10-27
US20050288312A1 (en) 2005-12-29
ES2314224T3 (es) 2009-03-16
WO2003074530A1 (en) 2003-09-12
US7091347B2 (en) 2006-08-15
AU2003210388B2 (en) 2007-05-17
AU2003210388A1 (en) 2003-09-16
PE20040189A1 (es) 2004-05-01
JP2005526057A (ja) 2005-09-02
TW200306194A (en) 2003-11-16
AR038864A1 (es) 2005-02-02
ATE410429T1 (de) 2008-10-15

Similar Documents

Publication Publication Date Title
PA8568401A1 (es) Inhibidores pirimidina y piridina biciclicos de la p38 quinasa
PA8632701A1 (es) Compuestos terapeuticos
HN2004000538A (es) "PIRIDO[ 2,3-d ] PIRIMIDINA-2,4-DIAMINAS COMO-INHIBIDORES DE PDE 2"
BR0308937A (pt) Compostos imidazo fundidos
HRP20070079A2 (en) Nucleoside phosphonate conjugates as anti hiv agents
GT200100151A (es) Derivados de 3-indolil-4-fenil-1h-pirrol-2,5-dione como inhibidores de glucogeno sintasa quinasa-3b.
CR6577A (es) Inhibidores triciclicos de poli(adp-ribosa) polimerasas
CL2010001486A1 (es) Compuestos derivados de [1,2,4]triazolo[1,5-a]piridina, inhibidores de jak; composicion farmaceutica; kit farmaceutico; su uso en el tratamiento de enfermedades tales como cancer, diabetes, enfermedad de alzheimer, enfermedad hepatica, trastornos del snc, entre otras.
PA8544901A1 (es) Derivados de oxazol
CR9234A (es) Derivados de 2,4(4,6) pirimidina
CR9149A (es) Derivados de rapamicina y los usos de los mismos en el tratamiento de trastornos neurologicos
BRPI0418031A (pt) inibidores de quinase fosfonato-substituìdos
UY28333A1 (es) Inhibidores de caspasa y sus usos.
BRPI0409367A (pt) derivados de piperidina inibidores de renina
PA8572101A1 (es) Inhibidores de metaloproteinasa de aril-heteroariloxi-ariloxi-pirimidina-2,4,6-triona
UY27774A1 (es) Inhibidores de metaloproteinas de triaril-oxi-aril-espiropirimidina-2,4,6-triona
UY30393A1 (es) Derivados sustituidos de la 1-piperidin-1-il-1,3-dihidro-2h-benzimidazol-2-ona, composiciones farmacéuticas conteniéndolos, procesos de preparación y aplicaciones
UY28536A1 (es) Derivados de bencimidazol, composiciones que los contienen, preparacion y usos de los mismos.
HN2003000379A (es) Derivados de anilinopirazol utiles en el tratamiento de la diabetes
PA8522501A1 (es) Derivados de pirrolidina
NI200300045A (es) Inhibidores de triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa.
PA8589801A1 (es) Aminoalcoxiindoles
PA8632601A1 (es) Derivados de pirimidina para tratar el crecimiento celular anómalo
UY29134A1 (es) Sulfonamidas sustituidas por derivados de bencimidazol, composiciones que la contienen, procedimiento de preparacion y aplicaciones
ATE368649T1 (de) Cyanoguanidin prodrugs